174 related articles for article (PubMed ID: 22699779)
1. Chemosaturation with percutaneous hepatic perfusion for unresectable isolated hepatic metastases from sarcoma.
Deneve JL; Choi J; Gonzalez RJ; Conley AP; Stewart S; Han D; Werner P; Chaudhry TA; Zager JS
Cardiovasc Intervent Radiol; 2012 Dec; 35(6):1480-7. PubMed ID: 22699779
[TBL] [Abstract][Full Text] [Related]
2. Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers.
Vogl TJ; Zangos S; Scholtz JE; Schmitt F; Paetzold S; Trojan J; Orsi F; Lotz G; Ferrucci P
Rofo; 2014 Oct; 186(10):937-44. PubMed ID: 24729409
[TBL] [Abstract][Full Text] [Related]
3. Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases.
Hughes MS; Zager J; Faries M; Alexander HR; Royal RE; Wood B; Choi J; McCluskey K; Whitman E; Agarwala S; Siskin G; Nutting C; Toomey MA; Webb C; Beresnev T; Pingpank JF
Ann Surg Oncol; 2016 Apr; 23(4):1309-19. PubMed ID: 26597368
[TBL] [Abstract][Full Text] [Related]
4. Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience.
Forster MR; Rashid OM; Perez MC; Choi J; Chaudhry T; Zager JS
J Surg Oncol; 2014 Apr; 109(5):434-9. PubMed ID: 24249545
[TBL] [Abstract][Full Text] [Related]
5. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery.
Dewald CLA; Becker LS; Maschke SK; Meine TC; Alten TA; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB
Clin Exp Metastasis; 2020 Dec; 37(6):683-692. PubMed ID: 33034815
[TBL] [Abstract][Full Text] [Related]
6. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience.
Artzner C; Mossakowski O; Hefferman G; Grosse U; Hoffmann R; Forschner A; Eigentler T; Syha R; Grözinger G
Cancer Imaging; 2019 May; 19(1):31. PubMed ID: 31146793
[TBL] [Abstract][Full Text] [Related]
7. Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review.
Vogel A; Gupta S; Zeile M; von Haken R; Brüning R; Lotz G; Vahrmeijer A; Vogl T; Wacker F
Adv Ther; 2017 Jan; 33(12):2122-2138. PubMed ID: 27798773
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of melphalan, oxaliplatin, and paclitaxel in colon, liver, and gastric cancer cell lines in a short-term exposure model of chemosaturation therapy by percutaneous hepatic perfusion.
Uzgare RP; Sheets TP; Johnston DS
Anticancer Res; 2013 May; 33(5):1989-2000. PubMed ID: 23645748
[TBL] [Abstract][Full Text] [Related]
9. Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial.
Meijer TS; Burgmans MC; Fiocco M; de Geus-Oei LF; Kapiteijn E; de Leede EM; Martini CH; van der Meer RW; Tijl FGJ; Vahrmeijer AL
Cardiovasc Intervent Radiol; 2019 Jun; 42(6):841-852. PubMed ID: 30767147
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors.
Kirstein MM; Marquardt S; Jedicke N; Marhenke S; Koppert W; Manns MP; Wacker F; Vogel A
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2113-2121. PubMed ID: 28634727
[TBL] [Abstract][Full Text] [Related]
11. Chemosaturation with Percutaneous Hepatic Perfusion: Outcome and Safety in Patients with Metastasized Uveal Melanoma.
Dewald CLA; Hinrichs JB; Becker LS; Maschke S; Meine TC; Saborowski A; Schönfeld LJ; Vogel A; Kirstein MM; Wacker FK
Rofo; 2021 Aug; 193(8):928-936. PubMed ID: 33535258
[TBL] [Abstract][Full Text] [Related]
12. Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases.
Carr MJ; Sun J; Cohen JB; Liu J; Serdiuk AA; Stewart SR; Doobay N; Duclos A; Seal DA; Choi J; Zager JS
Cancer Control; 2020; 27(1):1073274820983019. PubMed ID: 33372814
[TBL] [Abstract][Full Text] [Related]
13. Chemosaturation With Percutaneous Hepatic Perfusion in Unresectable Hepatic Metastases.
Glazer ES; Zager JS
Cancer Control; 2017 Jan; 24(1):96-101. PubMed ID: 28178721
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of chemosaturation in patients with hepatic metastases from uveal melanoma.
Estler A; Artzner C; Bitzer M; Nikolaou K; Hoffmann R; Hepp T; Hagen F; Eigentler T; Forschner A; Grözinger G
Acta Radiol; 2022 May; 63(5):577-585. PubMed ID: 34034537
[TBL] [Abstract][Full Text] [Related]
15. Phase II feasibility study on the combination of two different regional treatment approaches in patients with colorectal "liver-only" metastases: hepatic interstitial brachytherapy plus regional chemotherapy.
Wieners G; Pech M; Hildebrandt B; Peters N; Nicolaou A; Mohnike K; Seidensticker M; Sawicki M; Wust P; Ricke J
Cardiovasc Intervent Radiol; 2009 Sep; 32(5):937-45. PubMed ID: 19472000
[TBL] [Abstract][Full Text] [Related]
16. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy.
Alexander HR; Libutti SK; Bartlett DL; Pingpank JF; Kranda K; Helsabeck C; Beresnev T
Cancer; 2002 Aug; 95(4):730-6. PubMed ID: 12209715
[TBL] [Abstract][Full Text] [Related]
17. Embolization of variant hepatic arteries in patients undergoing percutaneous hepatic perfusion for unresectable liver metastases from ocular melanoma.
Meijer TS; Geus-Oei LF; Martini CH; Tijl FGJ; Sitsen ME; Erkel ARV; Meer RWV; Kapiteijn E; Vahrmeijer AL; Burgmans MC
Diagn Interv Radiol; 2019 Nov; 25(6):451-458. PubMed ID: 31650973
[TBL] [Abstract][Full Text] [Related]
18. Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104).
Bavisotto LM; Patel NH; Althaus SJ; Coldwell DM; Nghiem HV; Thompson T; Storer B; Thomas CR
Clin Cancer Res; 1999 Jan; 5(1):95-109. PubMed ID: 9918207
[TBL] [Abstract][Full Text] [Related]
19. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival.
Marquardt S; Kirstein MM; Brüning R; Zeile M; Ferrucci PF; Prevoo W; Radeleff B; Trillaud H; Tselikas L; Vicente E; Wiggermann P; Manns MP; Vogel A; Wacker FK
Eur Radiol; 2019 Apr; 29(4):1882-1892. PubMed ID: 30255257
[TBL] [Abstract][Full Text] [Related]
20. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options.
Agarwala SS; Eggermont AM; O'Day S; Zager JS
Cancer; 2014 Mar; 120(6):781-9. PubMed ID: 24301420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
